Ritter Pharmaceuticals (RTTR) Sets New 1-Year Low at $0.80

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as $0.80 and last traded at $0.82, with a volume of 9527 shares changing hands. The stock had previously closed at $1.07.

A number of equities research analysts recently issued reports on RTTR shares. Zacks Investment Research lowered shares of Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. HC Wainwright set a $15.00 price objective on shares of Ritter Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 15th. Finally, ValuEngine raised shares of Ritter Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, October 2nd.

The stock has a market cap of $5.37 million, a P/E ratio of -0.18 and a beta of 1.21.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, August 14th. The biotechnology company reported ($0.71) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.56) by ($0.15). On average, sell-side analysts forecast that Ritter Pharmaceuticals Inc will post -2.97 EPS for the current year.

In related news, Director Matthew W. Foehr bought 19,751 shares of the firm’s stock in a transaction on Friday, August 17th. The shares were bought at an average price of $2.04 per share, with a total value of $40,292.04. Following the completion of the transaction, the director now directly owns 54,751 shares of the company’s stock, valued at approximately $111,692.04. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 21.60% of the company’s stock.

WARNING: This news story was published by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this news story on another site, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this news story can be read at https://transcriptdaily.com/2018/11/10/ritter-pharmaceuticals-rttr-sets-new-1-year-low-at-0-80.html.

Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

See Also: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply